Shares of Veru Healthcare (NASDAQ: FHCO) are higher in Monday trade, moving on momentum from the recent launch of the company’s proprietary, over-the-counter PREBOOST® product to help prevent premature ejaculation (PE). As the only individually packaged medicated wipe that contains a desensitizing agent (4% benzocaine), PREBOOST allows for discrete, direct and precise dosage with each use. Top line results from an independent clinical study of PREBOOST show that men treated with PREBOOST had statistically significant improvement in their ability to control ejaculation, while 80% were no longer considered to have PE. The intended reach of PREBOOST is two-fold. On one hand, the product addresses the millions of men comprising the underserved PE market; the product also caters to couples looking to extend their sexual pleasure. From here, Veru said it will roll-out a sampling program for urologists, as well as engage a marketing partner, seek OTC distribution outlets, and pursue marketing opportunities abroad.
To view the full press release visit http://nnw.fm/6Jnh6
About Veru Healthcare
Veru Healthcare, a result of the acquisition of Aspen Park Pharmaceuticals by The Female Health Company (FHC), is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. To realize this goal, Veru Healthcare has three divisions: Pharmaceutical and Devices, Consumer Health Products, and Public Sector. For men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, prostate cancer, gout, and sexual dysfunction. Women’s Health has product candidates for female sexual health and advanced breast and ovarian cancers and markets FC2, a disposable contraceptive device, to OB GYN physicians and is the only female condom approved by FDA that offers dual protection against sexually transmitted infections, including HIV/AIDS and the Zika virus, and unintended pregnancy. The Female Health Company is tasked with managing the global public sector part of our business. Since The Female Health Company began distributing FC2 in 2007, the product has been shipped to 144 countries. The FC2 Female Condom® is the only currently available female-controlled product approved by FDA that offers dual protection against sexually transmitted infections, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies. For more information visit http://veruhealthcare.com/
About NetworkNewsBreak
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com.
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
